Kosowan Leanne, Chanchlani Rahul, Dart Allison, Wu Michael, Costa Rita, Singer Alexander
Department of Family Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Department of Paediatrics, McMaster University, Hamilton, Ontario, Canada.
Paediatr Child Health. 2024 Dec 23;30(3):140-149. doi: 10.1093/pch/pxae079. eCollection 2025 Jun.
We assessed trends in primary care paediatric blood pressure (BP) screening, follow-up, and treatment before and during the coronavirus disease 2019 (COVID-19) pandemic.
Retrospective cohort study using electronic medical records from the Canadian Primary Care Sentinel Surveillance Network to capture paediatric visits (aged 3 to 18) between January 1, 2011, and December 31, 2020. Time-series analysis was performed using documentation of monthly BP, high BP, follow-up of abnormal BP, and antihypertensive prescribing. We assessed differences between pre (January 1, 2011 to March 11, 2020) and during COVID-19 (March 12, 2020 to December 31, 2020).
Of 343,191 paediatric patients, 30.9% had ≥1 paediatric BP documented. Documentation of BP increased each year from 17.3% in 2011 to 19.8% in 2019 (β = 0.05, 95% CI 0.04, 0.07, P < 0.001), with a decrease in trend in 2020 to 11.0% (β = -16.95, 95% CI -18.91, -14.99, P < 0.001). There was an increasing pre-pandemic trend for laboratory screening and prescribing (β = 0.12, 95% CI 0.1, 0.14, P < 0.0001; β = 0.02, 95% CI 0.02, 0.02, P < 0.0001). During the COVID-19 pandemic, laboratory screening further increased (24.5% to 31.1%; β = 5.19, 95% CI 2.03, 8.35, P = 0.002), whereas there was no significant change in prescribing trends (1.3% to 1.4%; β = 0.15, 95% CI -0.01, 0.32, P = 0.07).
Documentation of BP increased annually, then declined precipitously during the COVID-19 pandemic. Despite lower BP screening and follow-up, the prevalence of hypertension and antihypertensive prescribing remained stable. Clinical practice trends in primary care highlight areas to improve the care and management of hypertensive paediatric patients.
我们评估了2019年冠状病毒病(COVID-19)大流行之前及期间初级保健中儿科血压(BP)筛查、随访及治疗的趋势。
采用回顾性队列研究,利用加拿大初级保健哨点监测网络的电子病历,收集2011年1月1日至2020年12月31日期间3至18岁儿童的就诊情况。使用每月血压、高血压、异常血压随访及抗高血压药物处方记录进行时间序列分析。我们评估了大流行前(2011年1月1日至2020年3月11日)与COVID-19期间(2020年3月12日至2020年12月31日)的差异。
在343,191名儿科患者中,30.9%有≥1次儿科血压记录。血压记录从2011年的17.3%逐年增加至2019年的19.8%(β = 0.05,95%可信区间0.04,0.07,P < 0.001),2020年趋势下降至11.0%(β = -16.95,95%可信区间-18.91,-14.99,P < 0.001)。大流行前实验室筛查和处方呈上升趋势(β = 0.12,95%可信区间0.1,0.14,P < 0.0001;β = 0.02,95%可信区间0.02,0.02,P < 0.0001)。在COVID-19大流行期间,实验室筛查进一步增加(从24.5%增至31.1%;β = 5.19,95%可信区间2.03,8.35,P = 0.002),而处方趋势无显著变化(从1.3%至1.4%;β = 0.15,95%可信区间-0.01,0.32,P = 0.07)。
血压记录逐年增加,在COVID-19大流行期间急剧下降。尽管血压筛查和随访减少,但高血压患病率和抗高血压药物处方保持稳定。初级保健中的临床实践趋势突出了改善高血压儿科患者护理和管理的领域。